Company intelligence / Profile preview

Hynson, Westcott & Dunning

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Lutrexin, a product for women's health indications, was withdrawn by FDA due to lack of adequate evidence for efficacy following the 1962 amendments requiring effectiveness as well as safety. The company challenged this withdrawal, resulting in a Supreme Court hearing on due process for regulatory drug approvals.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Pharma

Drug pipeline

1 asset

merbromin

Unknown

Beyond the preview

Go deeper on Hynson, Westcott & Dunning.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hynson, Westcott & Dunning.

Explore the full profile